| Yang Song,He Xiao,Chuan Chen,Ping Liang,Wenyuan Ji,Mingying Geng. Recombinant human vascular endostatin injection to synchronize craniospinal radiotherapy for the treatment of recurrent medulloblastoma in children: A retrospective clinical study. Oncol Transl Med, 2021, 7: 115-122. |
| 重组人血管内皮抑制素注射液同步全中枢放疗治疗儿童复发性髓母细胞瘤的回顾性临床研究 |
| Recombinant human vascular endostatin injection to synchronize craniospinal radiotherapy for the treatment of recurrent medulloblastoma in children: A retrospective clinical study |
| Received:April 12, 2021 Revised:June 16, 2021 |
| DOI：10.1007/s10330-021-0489-9 |
| 中文关键词: 重组人血管内皮抑制素注射液,全中枢放疗, 髓母细胞瘤 |
| 英文关键词: recombinant human vascular endostatin; craniospinal radiotherapy; medulloblastoma |
| 基金项目:重庆市科卫联合医学科研项目资助 (No. 2019MSXM079) |
| Author Name | Affiliation | E-mail | | Yang Song | Institute of Surgery Research, Daping Hospital, Army Medical University (Third Military Medical University) | songyang84zhu@163.com | | He Xiao | Institute of Surgery Research, Daping Hospital, Army Medical University (Third Military Medical University) | | | Chuan Chen | Institute of Surgery Research, Daping Hospital, Army Medical University (Third Military Medical University) | | | Ping Liang | Children''s Hospital Affiliated to Chongqing Medical University | | | Wenyuan Ji | Children''s Hospital Affiliated to Chongqing Medical University | | | Mingying Geng* | Institute of Surgery Research, Daping Hospital, Army Medical University (Third Military Medical University) | 380904661@qq.com |
|
| Hits: 5825 |
| Download times: 6650 |
| 中文摘要: |
| 目的: 髓母细胞瘤是最常见的儿童原发性中枢神经系统恶性肿瘤,对于复发性髓母细胞瘤没有标准治疗模式。本研究的目的是探讨重组人血管内皮抑制素注射液联合全中枢放疗治疗复发性儿童髓母细胞瘤的临床价值和毒副反应。
方法: 本研究回顾性分析13例复发性髓母细胞瘤患者，年龄范围在5 ~ 18岁。7例儿童采用便携式微量匀速输液泵泵注恩度同步全中枢放疗，放疗开始前3天开始泵注，恩度剂量为7.5mg/m2/d，连续使用7天，停药7天，为一个周期。放疗期间反复应用，直至放疗结束(实验组)。其余6例仅行全中枢放疗(对照组)。
结果: 实验组完全缓解率为71.4%，对照组为16.7%。实验组和对照组的中位无进展生存期分别为14个月(95%CI: 0.0-29.60)和19个月(95%CI: 0.0-39.53)。实验组和对照组的中位总生存期分别为19个月(95%CI: 0.0-38.20)和23个月(95%CI: 2.47-43.53)。最常见的不良事件包括1级血小板减少(7.7%)、3级中性粒细胞减少(38.5%)和1级贫血(30.8%)。
结论: 恩度同步全中枢放疗显著提高复发性髓母细胞瘤患儿的完全缓解率，没有增加放疗的副作用，但没有提高无进展生存期和总生存期。 |
| 英文摘要: |
| Objective Medulloblastoma (MB) is the most common primary central nervous system malignancy in
children. Nonetheless, there is no standard treatment for recurrent MB. The purpose of this study was to
investigate the clinical value and toxicity of recombinant human endostatin injection (Endostar®) combined
with craniospinal radiotherapy for the treatment of recurrent MB in children.
Methods This study retrospectively analyzed 13 patients with recurrent MB aged 5–18 years. Endostar®
7.5 mg/m2/d was synchronized during craniospinal radiotherapy for 7 children with a portable micro uniform
speed infusion pump. Endostar® was applied 3 days prior to the initiation of radiotherapy. The drug was in
continuous use for 7 days. Similarly, the withdrawal of the drug took place over 7 days. This represented a
cycle. During radiotherapy, the application was repeated until the end of radiotherapy (experimental group).
In the other 6 cases, only craniospinal radiotherapy was used (control group).
Results The complete remission rate was 71.4% in the experimental group and 16.7% in the control
group. The median progression-free survival (PFS) was 14 months (95% CI: 0.0–29.60) and 19 months
(95% CI: 0.0–39.53) in the experimental and control groups, respectively. The median overall survival (OS)
was 19 months (95% CI: 0.0–38.20) and 23 months (95% CI: 2.47–43.53) in the experimental and control
groups, respectively. The most common adverse events included grade 1 thrombocytopenia (7.7%), grade
3 neutropenia (38.5%), and grade 1 anemia (30.8%).
Conclusion Endostar® synchronizing craniospinal radiotherapy significantly improved the complete
response rate of children with recurrent MB. It did not increase the side effects of radiation therapy.
However, it did not improve the PFS or OS. |
|
View Full Text
Download reader HTML全文 |
| Close |